Akèy › Osteyosakòm
Etid klinik pou Osteyosakòm ap rekrite nan Etazini
52 etid pou Osteyosakòm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Memphis, TN10 etid
- St. Louis, MO10 etid
- Atlanta, GA10 etid
- Boston, MA9 etid
- Mountain View, CA8 etid
- Chicago, IL7 etid
- Birmingham, AL7 etid
- Houston, TX7 etid
- Los Angeles, CA7 etid
- Tampa, FL6 etid
- Washington, DC6 etid
- New York City, NY6 etid
- Cincinnati, OH6 etid
- Philadelphia, PA6 etid
- Aurora, CO6 etid
- Dallas, TX5 etid
- Honolulu, HI5 etid
- The Bronx, NY5 etid
- Durham, NC5 etid
- Gainesville, FL4 etid
- Orlando, FL4 etid
- Clifton, NJ4 etid
- Harrisburg, PA4 etid
- San Francisco, CA4 etid
- Columbus, OH4 etid
- Oakland, CA4 etid
- Salt Lake City, UT4 etid
- San Diego, CA4 etid
- Cleveland, OH4 etid
- Seattle, WA4 etid
- Baltimore, MD4 etid
- Queens, NY4 etid
- Greenburgh, NY4 etid
- Little Rock, AR3 etid
- Nashville, TN3 etid
- Hartford, CT3 etid
- Miami, FL3 etid
- Milwaukee, WI3 etid
- Jacksonville, FL3 etid
- Ann Arbor, MI3 etid
Pa eta
- Alabama7 etid
- Arizona5 etid
- Arkansas3 etid
- Ayiti5 etid
- Colorado6 etid
- Connecticut4 etid
- Distrik Columbia5 etid
- Florid10 etid
- Georgia10 etid
- Illinois7 etid
- Kalifòni18 etid
- Lwizyàn3 etid
- Maryland5 etid
- Massachusetts9 etid
- Michigan6 etid
- Minnesota3 etid
- Missouri10 etid
- New Jersey6 etid
- New York11 etid
- North Carolina6 etid
- Ohio12 etid
- Oregon3 etid
- Pennsylvania9 etid
- Rhode Island3 etid
- South Carolina3 etid
- Tennessee12 etid
- Texas10 etid
- Utah4 etid
- Virginia3 etid
- Washington4 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Ap rekriteFaz 1
Jiska laj 50 · Tout sèks · Mizajou Sep 30, 2026 · NCT06492954Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Ap rekriteFaz 2
Laj 7 a 22 · Tout sèks · Mizajou Sep 25, 2026 · NCT07560826Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Ap rekriteFaz 1/2
Jiska laj 26 · Tout sèks · Mizajou Sep 3, 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262Clinical Orthopaedic Data Bank (Acute and Chronic)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 3, 2026 · NCT00411060Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Ap rekriteFaz 1/2
Laj 12 a 40 · Tout sèks · Mizajou Sep 3, 2026 · NCT07725380Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Ap rekriteFaz 1
Laj 5 a 40 · Tout sèks · Mizajou Sep 3, 2026 · NCT06156410Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Ap rekriteFaz 1
Laj 1 a 75 · Tout sèks · Mizajou Sep 1, 2026 · NCT07227571Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Ap rekriteFaz 2
Jiska laj 21 · Tout sèks · Mizajou Sep 1, 2026 · NCT07428993Losartan + Sunitinib in Treatment of Osteosarcoma
Ap rekriteFaz 1
Laj 10 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT03900793Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Ap rekriteFaz 3
Jiska laj 50 · Tout sèks · Mizajou Aug 25, 2026 · NCT05235165Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Ap rekrite
Tout laj · Tout sèks · Mizajou Aug 21, 2026 · NCT07514819SPEARHEAD-3 Pediatric Study
Ap rekriteFaz 1/2
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT05210374Musculoskeletal Cancers Remote Monitoring and Care
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07129226NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07628634Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT04040205AOH1996 for the Treatment of Refractory Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT05227326NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Ap rekriteFaz 1
Laj 1 a 24 · Tout sèks · Mizajou Jul 21, 2026 · NCT07211737Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Ap rekriteFaz 1
Laj 12 a 50 · Tout sèks · Mizajou Jul 15, 2026 · NCT03093909Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Ap rekriteFaz 2
Laj 0 a 50 · Tout sèks · Mizajou Jul 9, 2026 · NCT07321912Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Jun 30, 2026 · NCT06625190Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.